ICONOVIR BIO
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.
ICONOVIR BIO
Social Links:
Industry:
Biotechnology
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.iconovir.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
77 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Sitelinks Search Box
Similar Organizations
Atavistik Bio
Atavistik Bio is a biotechnology company that focuses on the discovery and development of novel therapies for metabolic diseases and cancer.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Vida Ventures
Vida Ventures investment in Series A - IconOVir Bio
Polaris Partners
Polaris Partners investment in Series A - IconOVir Bio
Logos Capital
Logos Capital investment in Series A - IconOVir Bio
Nextech Invest
Nextech Invest investment in Series A - IconOVir Bio
Bellco Capital
Bellco Capital investment in Series A - IconOVir Bio
Wellington Partners
Wellington Partners investment in Series A - IconOVir Bio
GV
GV investment in Series A - IconOVir Bio
Two River
Two River investment in Series A - IconOVir Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-06 | IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer |
Official Site Inspections
http://www.iconovir.com Semrush global rank: 4.34 M Semrush visits lastest month: 2.62 K
- Host name: cloudproxy10082.sucuri.net
- IP address: 192.124.249.82
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "IconOVir Bio"
About Us - IconOVir
IconOVir Bio 689 Fifth Ave, 12 th Floor New York, NY 10022 ©2024 IconOVir Bio ...See details»
IconOVir Bio - Crunchbase Company Profile & Funding
IconOVir Bio is a preclinical-stage biotechnology company developing oncolytic virus therapy for the treatment of patients with cancer. Its oncolytic virus platform is designed to address key …See details»
IconOVir Bio Announces Formation of Scientific Advisory Board
Apr 20, 2021 It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients. For more information, please …See details»
IconOVir Bio, Inc. Company Profile | New York, NY | Competitors ...
Find company research, competitor information, contact details & financial data for IconOVir Bio, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
IconOVir Bio - Funding, Financials, Valuation & Investors
IconOVir Bio is a preclinical-stage biotechnology company developing oncolytic virus therapy for the treatment of patients with cancer. Search Crunchbase. ... How much funding has this …See details»
IconOVir Bio Company Profile 2024: Valuation, Funding …
What industry is IconOVir Bio in? IconOVir Bio’s primary industry is Biotechnology. Is IconOVir Bio a private or public company? IconOVir Bio is a Private company. What is IconOVir Bio’s current revenue? The current …See details»
IconOVir Bio - VentureRadar
IconOVir’s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. It is designed to address key limitations …See details»
IconOVir Bio - Craft
IconOVir Bio is a preclinical-stage biotechnology company that develops therapies to improve the treatment of patients with cancer. Its proprietary oncolytic virus platform is based designed to …See details»
IconOVir Bio Raises $77 Million in Series A Financing to Develop …
SAN DIEGO, January 5, 2021 – IconOVir Bio, Inc., a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients …See details»
A new, well-connected biotech aims to fight cancer with viruses
Jan 5, 2021 With fresh cash in hand, IconOVir aims to get that lead therapy, known as IOV-1042, into clinical testing in the first half of 2022. McCamish said there is a follow-on program …See details»
IconOVir uncloaks with $77M, ex-Forty Seven CEO and cancer …
Jan 5, 2021 IconOVir wants to get IOV-1042 into the clinic in the first half of 2022, McCamish said. A big focus will be on manufacturing the virus for clinical trials and designing a phase 1 …See details»
Two Companies Ring in 2021 with Cash for Cancer and Rare Diseases
Jan 5, 2021 IconOVir’s lead candidate, IOV-1042 is derived from the common cold virus. Preclinical research has shown that IOV-1042 infects and kills a broad range of tumor cells, …See details»
IconOVir Bio - workinbiotech.com
Iconovir Bio is a preclinical-stage biotechnology company developing next-generation oncolytic virus therapies to improve the treatment of cancer. Oncolytic viruses are viruses that are …See details»
IconOVir Bio Announces First Patient Dosed in Phase 1 Clinical …
IconOVir’s Phase 1 clinical trial is an open-label study designed to evaluate the safety, pharmacokinetics, pharmacodynamics and biological and clinical activity of ICVB-1042 in …See details»
IconOVir Bio Raises $77 Million in Series A Financing to Develop …
Jan 5, 2021 For more information, please visit www.iconovir.com and follow IconoVir on LinkedIn. Contacts Company Contact: Ben Stone [email protected] 1-858-224-1900 Media …See details»
IconOVir doses first patient in trial of ICVB-1042 for solid tumours
Jul 12, 2023 IconOVir Bio has dosed the first patient in its Phase I dose escalation and expansion clinical trial of ICVB-1042 to treat advanced solid tumours. The open-label study …See details»
IconOVir Bio Announces Preclinical Proof-of-Concept Data for ...
SAN DIEGO, CA., May 20, 2021 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the …See details»
IconOVir Bio Announces Preclinical Proof-of-Concept Data for ...
May 20, 2021 IconOVir is advancing ICVB-1042 through preclinical development, with plans to file an Investigational New Drug application with the U.S. Food and Drug Administration in the …See details»
IconOVir Bio Announces Preclinical Proof-of-Concept Data for ...
May 20, 2021 IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of …See details»